A prospective study of serum soluble CD30 in allogeneic hematopoietic stem cell transplantation

Transplant Immunology

Volumn 23, Issue 4, 2010, Pages 215-219

  Hübel, Kai ^a   Cremer, Birgit ^a   Heuser, Eva ^a   von Strandmann, Elke Pogge ^a   Hallek, Michael ^a   Hansen, Hinrich P ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Acute graft versus host disease; Allogeneic; Soluble CD30; Stem cell transplantation

Indexed keywords

AMSACRINE; BUSULFAN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THIOTEPA; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE SEVERITY; ENGRAFTMENT; FEMALE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HUMAN CELL; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ADULT; AGED; ANTIGENS, CD30; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 77956062895     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2010.07.001     Document Type: Article

References (26)

1. Schwab U., Stein H., Gerdes J., Lemke H., Kirchner H., Schaadt M., et al. Production of a antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982, 299:65-67.
2. Smith C.A., Farrah T., Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994, 76:959-962.
3. Stanciu L.A., Roberts K., Lau L.C., Coyle A.J., Johnston S.L. Induction of type 2 activity in adult human CD8+ T cells by repeated stimulation and IL-4. Int Immunol 2001, 13:341-348.
4. Cambiaggi A., Cantoni C., Marciano S., De Totero D., Pileri S., Tazzari P.L., et al. Cultured human NK cells express the Ki-1/CD30 antigen. Br J Hematol 1993, 85:270-276.
5. Pellegrini P., Totaro R., Contasta I., Berghella A.M., Carolei A., Adorno D. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune response and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis. Neuroimmunomodulation 2005, 12:220-234.
6. Pellegrini P., Berghella A.M., Contasta I., Adorno D. CD30 antigen: not a physiological marker for Th2 cells but an important costimulatory molecule in the regulation of the balance between Th1/Th2 response. Transpl Immunol 2003, 12:49-61.
7. Hansen H.P., Dietrich S., Kisseleva T., Mokros T., Mentlein R., Lange H.H., et al. CD30 shedding from karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. J Immunol 2000, 165:6703-6709.
8. Bengtsson A. The role of CD30 in atopic disease. Allergy 2001, 56:593-603.
9. Nikaein A., Spiridon C., Hunt J., Rosenthal J., Anderson A., Eichhorn E., et al. Pre-transplant level of soluble CD30 is associated with infection after heart transplantation. Clin Transplant 2007, 21:744-747.
10. Pizzolo G., Vinante F., Nadali G., Krampera M., Morosato L., Chilosi M., et al. High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol 1997, 108:251-253.
11. Nishioka C., Takemoto S., Kataoka S., Yamanaka S., Moriki T., Shoda M., et al. Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Sci 2005, 96:810-815.
12. Rezaei N., Haji-Molla-Hoseini M., Aghamohammadi A., Pourfathollah A.A., Moghtadaie M., Pourpak Z. Increased serum levels of soluble CD30 in patients with common variable immunodeficiency and its clinical implications. J Clin Immunol 2008, 28:78-84.
13. Purdue M.P., Lan Q., Martinez-Maza O., Oken M.M., Hocking W., Huang W.Y., et al. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood 2009, 114:2730-2732.
14. Domingues EM, Matuck T, Graciano ML, Souza E, Rioja S, Falci MC, et al. Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant. Clin Transplant in press.
15. Frisaldi E., Conca R., Magistroni P., Fasano M.E., Mazzola G., Patane F., et al. Prognostic values of soluble CD30 and CD30 gene polymorphisms in heart transplantation. Transplantation 2006, 81:1153-1156.
16. Saini D., Ramachandran S., Nataraju A., Benshoff N., Liu W., Desai N., et al. Activated effector and memory T cells contribute to circulating sCD30: potential marker for islet allograft rejection. Am J Transplant 2008, 8:1798-1808.
17. Shah A.S., Lefell M.S., Lucas D., Zachary A.A. Elevated pretransplantation soluble CD30 in associated with decreased early allograft function after human lung transplantation. Hum Immunol 2009, 70:101-103.
18. Fabrega E., Unzueta M.G., Cobo M., Casafont F., Amado J.A., Romero F.P. Value of soluble CD30 in liver transplantation. Transplant Proc 2007, 39:2295-2296.
19. Matinlauri I., Hockerstedt K., Isoniemi H. High serum soluble CD30 does not predict acute rejection in liver transplant patients. Transplant Proc 2006, 38:3601-3604.
20. Bacigalupo A. Management of acute graft-versus-host-disease. Br J Hematol 2007, 137:87-98.
21. Ferrara J.L.M., Antin J. The pathophysiology of graft-versus-host disease. Thoma's hematopoietic cell transplantation 2004, 353-368. Blackwell Publishing Inc, Malden. K.G. Blume, S.J. Forman, F.R. Appelbaum (Eds.).
22. Zeiser R., Nguyen V.H., Hou J.Z., Beilhack A., Zambricki E., Buess M., et al. Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood 2007, 109:2225-2233.
23. Schlaf G., Altermann W.W., Rothhoff A., Seliger B. Soluble CD30 serum level - an adequate marker for allograft rejection of solid organs?. Histol Histopathol 2007, 22:1269-1279.
24. Casasnovas R.O., Mounier N., Brice P., Divine M., Morschhauser F., Gabarre J., et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Group d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007, 25:1732-1740.
25. Nagahama M., Nomura S., Katsura K., Ozaki Y., Yoshimura C., Kagawa H, et al. Serum levels of soluble CD30 in autologous peripheral blood stem cell transplantation. J Cancer Res Clin Oncol 2000, 126:101-106.
26. Waldmann T. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 1993, 14:264-270.